Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T18:20:56.512Z Has data issue: false hasContentIssue false
  • English
  • Français

Sertraline in the prevention of depression

Published online by Cambridge University Press:  02 January 2018

Jan M. Keppel Hesselink  and
Perry M. C. de Jongh
Jan M. Keppel Hesselink
Affiliation:
Medical Department, Bayer Netherlands, Nijverheidsweg 26, Mijdrecht, The Netherlands
Perry M. C. de Jongh
Affiliation:
Medical Department, Bayer Netherlands, Nijverheidsweg 26, Mijdrecht, The Netherlands
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 161 , Issue 2 , August 1992 , pp. 270 - 271
Copyright
Copyright © 1992 The Royal College of Psychiatrists 

References

Commission of the European Communities (1989) The Rules Governing Medicinal Products in the European Community, III, 209–218.Google Scholar
Lee, J. H. (1990a) Clinical review of efficacy data. In NDA-19–839 Sertraline: Safety and Efficacy Considerations for Use in the Management of Depression, pp. 7–19. Psychopharmacological drugs advisory committee, Rockville, USA: Food and Drug Administration.Google Scholar
Lee, J. H. (1990b) Summary Basis of Approval: Statistical Review and Evaluation of Sertraline HCL, NDA #19–436. Rockville, USA: Food and Drug Administration.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.